文献速递免疫规划卫生政策与健康促进

中国女性巨细胞病毒疫苗接种的成本效果:一项决策分析马尔可夫研究

Cost-effectiveness of cytomegalovirus vaccination for females in China: A decision-analytical Markov study.
PubMed 文献 · Vaccine · 2023-08-12

本研究构建决策树马尔可夫模型,模拟婴儿、青少年(10岁)和年轻成人(20岁)三个队列各100万人群的巨细胞病毒疫苗接种策略。假设疫苗效力50%、保护20年、覆盖率70%、价格120美元/剂。结果显示,感染前效力型疫苗青少年策略最具成本效果,ICER为12213美元/避免DALY;感染前后效力型疫苗年轻成人策略可节省成本。

要点

  • 感染前效力型疫苗,青少年策略最具成本效果,ICER为12213美元/避免DALY。
  • 感染前后效力型疫苗,年轻成人策略可节省成本。
  • 疫苗价格影响最优策略选择,主结果在敏感性分析下稳健。

核心结论

  • 中国女性巨细胞病毒疫苗接种具有成本效果,甚至可节省成本。
  • 研究结果对巨细胞病毒疾病控制具有公共卫生意义。

研究设计与样本

  • 决策树马尔可夫模型,模拟婴儿、青少年(10岁)和年轻成人(20岁)三个队列各100万人群的疫苗接种策略。
  • 假设疫苗效力50%、保护20年、覆盖率70%、价格120美元/剂(基础分析)。
  • 成本和伤残调整生命年(DALY)按每年3%贴现,ICER低于2021年中国人均GDP(12500美元)视为具有成本效果。

主要发现

  • 感染前效力型疫苗:青少年策略最具成本效果,ICER为12213美元(12134至12291)每避免DALY,与次优策略(年轻成人策略)相比。
  • 感染前后效力型疫苗:年轻成人策略最具成本效果,可节省成本。
  • 单因素分析中,感染前效力型疫苗价格≤60美元/剂时婴儿策略占优,61至121美元/剂时青少年策略占优,122至251美元/剂时年轻成人策略占优。
  • 感染前后效力型疫苗价格超过226美元/剂前,年轻成人策略持续为优选策略。
  • 主结果在多种敏感性分析和情景分析下稳健。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The global burden of disease caused by congenital cytomegalovirus (CMV) infection is high. Previous modeling studies have suggested that CMV vaccination may be cost-effective in developed countries. Congenital CMV infection is more likely driven by maternal non-primary infection in China. We aimed to measure the effectiveness and cost-effectiveness of population-level CMV vaccination in Chinese females. METHODS: A decision tree Markov model was developed to simulate potential CMV vaccination strategies in a multi-cohort setting, with a population size of 1,000,000 each for the infant, adolescent (10-year-old) and young adult (20-year-old) cohorts. The hypothetical vaccines were assumed to have 50% efficacy, 20 years of protection, 70% coverage, at a price of US$120/dose for base-case analysis. Costs and disability-adjusted life years (DALYs) were discounted by 3% per year and the vaccination would be considered cost-effective if an incremental cost-effectiveness ratio (ICER) was lower than 2021 Chinese per capita GDP (US$12,500). FINDINGS: For the pre-infection (PRI) vaccine efficacy type, the adolescent strategy was the most cost-effective, with an ICER of US$12,213 (12,134 to 12,291) pre DALY averted, compared with the next best strategy (young adult strategy). For pre- and post-infection (P&PI) efficacy type, the young adult strategy was the most cost-effective as it was cost-saving. In one-way analysis varying the PRI vaccine price, the infant strategy, adolescent strategy and the young adult strategy would be a dominant strategy over others if the vaccine cost ≤US$60, US$61-121 and US$122-251 per dose respectively. In contrast, the young adult strategy continued to be the preferred strategy until the P&PI vaccine price exceeded US$226/dose. Our main results were robust under a wide variety of sensitivity analyses and scenario analyses. INTERPRETATION: CMV vaccination for females would be cost-effective and even cost-saving in China. Our findings had public health implications for control of CMV diseases.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yin MZ, Gu YY, Shu JT, et al. Cost-effectiveness of cytomegalovirus vaccination for females in China: A decision-analytical Markov study. Vaccine. 2023. PMID: 37580210. doi:10.1016/j.vaccine.2023.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。